Showing results (191-200 of 247) with videos related to
Sort By:
Pageof 25
Cancer Chemotherapy and Pharmacology|August 10, 2006
Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: novel targets for therapyRobert L Fine, Samir S Shah, Thomas A Moulton, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2017
Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid TumorsHoward A Burris, Jeffrey R Infante, Stephen M Ansell, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2013
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapyGail D Lewis Phillips, Carter T Fields, Guangmin Li, et al.Investigational New Drugs|April 4, 2018
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumorsCarol Aghajanian, Katherine M Bell-McGuinn, Howard A Burris, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2018
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human StudyDejan Juric, Jordi Rodon, Josep Tabernero, et al.Molecular Oncology|May 28, 2025
Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumabCharles Swanton, Russell W Madison, Candice Francheska B Tambaoan, et al.The New England Journal of Medicine|December 14, 2011
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancerJosé Baselga, Mario Campone, Martine Piccart, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2017
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Carcinoma or Other Solid TumorsRebecca Kristeleit, Geoffrey I Shapiro, Howard A Burris, et al.Cancer Chemotherapy and Pharmacology|January 19, 2017
Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancerJeffrey R Infante, Amita Patnaik, Claire F Verschraegen, et al.Nature Communications|January 6, 2025
MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trialMrinal Gounder, Melissa Johnson, Rebecca S Heist, et al.Pageof 25